Vector Science & Therapeutics announced that it has signed a three-year development and manufacturing partnership with MPP Group LLC to produce pharmaceutical-grade peptides and manufacture Vector’s drug delivery devices. MPP is headquartered in Mequon.
The collaboration brings together peptide formulation, analytical testing, and Vector’s proprietary transdermal delivery system within a single FDA-registered, cGMP-compliant facility. By centralizing these capabilities, the companies aim to shorten development timelines while maintaining quality control throughout the manufacturing and delivery process. The agreement also supports Vector’s expansion into the rapidly growing $80.8 billion peptide therapeutics market through the development of pharmaceutical-grade, shelf-stable peptide products.
Key Details of the Agreement
Access to FDA-registered cGMP infrastructure: Through the partnership, Vector gains access to MPP’s Wisconsin manufacturing site, avoiding an estimated $6 million in facility-related capital investment. Development of 22 peptide formulations: The companies plan to co-develop stable formulations with shelf lives of up to 24 months. This includes 14 peptides that recently regained eligibility for compounding under physician oversight after being removed from the FDA Category 2 list. Dedicated manufacturing equipment: Vector will finance peptide production equipment exclusively for its own product line while retaining ownership rights and the ability to reclaim the equipment if the agreement ends. Expansion into the peptide therapeutics sector: The arrangement is intended to strengthen Vector’s physician-focused distribution network and support commercialization of its transdermal delivery technology. The collaboration brings together peptide formulation, analytical testing, and Vector’s proprietary transdermal delivery system within a single FDA-registered, cGMP-compliant facility. By centralizing these capabilities, the companies aim to shorten development timelines while maintaining quality control throughout the manufacturing and delivery process. The agreement also supports Vector’s expansion into the rapidly growing $80.8 billion peptide therapeutics market through the development of pharmaceutical-grade, shelf-stable peptide products.
Key Details of the Agreement
As part of the partnership, Vector and MPP will jointly create proprietary purity and potency testing methods, which will remain confidential trade secrets shared exclusively between the two organizations. Manufacturing activities and formulation development are expected to begin in May 2026.
The peptide portfolio covered under the agreement includes compounds such as BCP-157, TB-500, PT-141, Sermorelin, CJC-1295, Ipamorelin, MOTS-c, GHK-Cu, DSIP, KPV, Retatrutide, Kisspeptin, Epitalon, Dihexa, Semax, LL-37, Selank, SS-31, Melanotan II, Ibutamoren Mesylate, and NAD.
Tommy Thompson, Chairman of Vector, emphasized that access to an FDA-registered, cGMP-compliant facility is essential for companies focused on pharmaceutical-grade therapeutics. He noted that the agreement provides Vector with a strong manufacturing base in Wisconsin and enables the company to apply regulated drug-production standards to its peptide pipeline from the outset.
Bill Jackson stated that the partnership allows Vector to maintain direct oversight of manufacturing equipment, formulations, and production processes while working with a local pharmaceutical-grade manufacturing partner. He described the agreement as a critical step in establishing the company’s distribution network for its transdermal delivery platform.
Dr. Brad Worthington highlighted the growing clinical promise of peptide therapeutics across multiple medical applications. He explained that broader adoption has often been hindered by issues related to formulation stability, delivery accuracy, and administration methods. According to Worthington, the collaboration with MPP is intended to address these challenges through the development of stable, pharmaceutical-grade peptide formulations in a cGMP environment, helping advance clinician-guided peptide delivery technologies with improved precision.
The peptide portfolio covered under the agreement includes compounds such as BCP-157, TB-500, PT-141, Sermorelin, CJC-1295, Ipamorelin, MOTS-c, GHK-Cu, DSIP, KPV, Retatrutide, Kisspeptin, Epitalon, Dihexa, Semax, LL-37, Selank, SS-31, Melanotan II, Ibutamoren Mesylate, and NAD.
Tommy Thompson, Chairman of Vector, emphasized that access to an FDA-registered, cGMP-compliant facility is essential for companies focused on pharmaceutical-grade therapeutics. He noted that the agreement provides Vector with a strong manufacturing base in Wisconsin and enables the company to apply regulated drug-production standards to its peptide pipeline from the outset.
Bill Jackson stated that the partnership allows Vector to maintain direct oversight of manufacturing equipment, formulations, and production processes while working with a local pharmaceutical-grade manufacturing partner. He described the agreement as a critical step in establishing the company’s distribution network for its transdermal delivery platform.
Dr. Brad Worthington highlighted the growing clinical promise of peptide therapeutics across multiple medical applications. He explained that broader adoption has often been hindered by issues related to formulation stability, delivery accuracy, and administration methods. According to Worthington, the collaboration with MPP is intended to address these challenges through the development of stable, pharmaceutical-grade peptide formulations in a cGMP environment, helping advance clinician-guided peptide delivery technologies with improved precision.